early

Health Canada Grants Authorization for LEQEMBI (lecanemab) for the Treatment of Early Alzheimers DiseaseHealth Canada Grants Authorization for LEQEMBI (lecanemab) for the Treatment of Early Alzheimers Disease

Health Canada Grants Authorization for LEQEMBI (lecanemab) for the Treatment of Early Alzheimers Disease

In Canada, lecanemab is indicated for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment or…

1 week ago
ACM Biolabs Reports Favorable Safety Signals and Early Pharmacodynamics from Intramuscular Administration of ACM-CpG in Patients with Advanced Solid TumorsACM Biolabs Reports Favorable Safety Signals and Early Pharmacodynamics from Intramuscular Administration of ACM-CpG in Patients with Advanced Solid Tumors

ACM Biolabs Reports Favorable Safety Signals and Early Pharmacodynamics from Intramuscular Administration of ACM-CpG in Patients with Advanced Solid Tumors

SINGAPORE, Oct. 22, 2025 /PRNewswire/ -- ACM Biolabs, a clinical-stage biotechnology company developing next-generation nanoparticle-based immunotherapies, today announced encouraging early clinical findings…

2 weeks ago
Galeries Lafayette to open doors in India with Aditya Birla Group early next monthGaleries Lafayette to open doors in India with Aditya Birla Group early next month

Galeries Lafayette to open doors in India with Aditya Birla Group early next month

The debut flagship in Mumbai's Kala Ghoda district will bring global fashion, beauty, and experiential retail to India's luxury market…

2 weeks ago
AAF Management Closes $55M for Early Stage Hybrid FundAAF Management Closes $55M for Early Stage Hybrid Fund

AAF Management Closes $55M for Early Stage Hybrid Fund

Washington, D.C., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Venture capital firm AAF announced today that it has closed a $55M…

3 weeks ago
LEQEMBI (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimers Disease Approved in ChinaLEQEMBI (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimers Disease Approved in China

LEQEMBI (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimers Disease Approved in China

September 28, 2025 19:30 ET  | Source: Biogen Inc. TOKYO and CAMBRIDGE, Mass., Sept. 28, 2025 (GLOBE NEWSWIRE) -- Eisai…

1 month ago
LANZAJET – AN EARLY MOVER IN AUSTRALIA – APPLAUDS THE AUSTRALIAN GOVERNMENT’S LEADERSHIP AND GAME-CHANGING $1.1B (AUD) INVESTMENT TO ADVANCE SUSTAINABLE FUELSLANZAJET – AN EARLY MOVER IN AUSTRALIA – APPLAUDS THE AUSTRALIAN GOVERNMENT’S LEADERSHIP AND GAME-CHANGING $1.1B (AUD) INVESTMENT TO ADVANCE SUSTAINABLE FUELS

LANZAJET – AN EARLY MOVER IN AUSTRALIA – APPLAUDS THE AUSTRALIAN GOVERNMENT’S LEADERSHIP AND GAME-CHANGING $1.1B (AUD) INVESTMENT TO ADVANCE SUSTAINABLE FUELS

LanzaJet's Alcohol-to-Jet technology for sustainable fuel production is key to enabling the development of the industry in Australia while strengthening…

2 months ago
The Aleo Network Foundation Joins Binance Alpha, Expanding Early Access to Privacy-First BlockchainThe Aleo Network Foundation Joins Binance Alpha, Expanding Early Access to Privacy-First Blockchain

The Aleo Network Foundation Joins Binance Alpha, Expanding Early Access to Privacy-First Blockchain

Binance Alpha Pre-Listing Program Makes the ALEO Token Accessible to Millions of Users Worldwide Within the Binance Ecosystem SAN FRANCISCO,…

2 months ago
Eisai Initiated Rolling Supplemental Biologics License Application to the U.S. FDA for LEQEMBI IQLIK(lecanemab-irmb) as a Subcutaneous Starting Dose for the Treatment of Early Alzheimers Disease Under Fast Track StatusEisai Initiated Rolling Supplemental Biologics License Application to the U.S. FDA for LEQEMBI IQLIK(lecanemab-irmb) as a Subcutaneous Starting Dose for the Treatment of Early Alzheimers Disease Under Fast Track Status

Eisai Initiated Rolling Supplemental Biologics License Application to the U.S. FDA for LEQEMBI IQLIK(lecanemab-irmb) as a Subcutaneous Starting Dose for the Treatment of Early Alzheimers Disease Under Fast Track Status

LEQEMBI IQLIK, if approved for initiation dosing, would be the first and only anti-amyloid treatment to offer at-home injection from…

2 months ago
How Sparkvia AI Website Tool Proves Real AI Utility on XRP SPARK Public Sale is Open for Early InvestorsHow Sparkvia AI Website Tool Proves Real AI Utility on XRP SPARK Public Sale is Open for Early Investors

How Sparkvia AI Website Tool Proves Real AI Utility on XRP SPARK Public Sale is Open for Early Investors

VALLETTA, Malta, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Sparkvia AI has officially opened the public sale of its utility token,…

2 months ago
Novartis Leqvio shows statistically significant and clinically meaningful early LDL-C goal achievement with less muscle painNovartis Leqvio shows statistically significant and clinically meaningful early LDL-C goal achievement with less muscle pain

Novartis Leqvio shows statistically significant and clinically meaningful early LDL-C goal achievement with less muscle pain

V-DIFFERENCE is first study to show that Leqvio prioritized after statins helps more patients achieve guideline low-density lipoprotein cholesterol (LDL-C)…

2 months ago
Show more Posts